Velásquez BM, Gil-Villa AM, Cadavid JAP

Idioma: Español
Referencias bibliográficas: 50
Paginas:
Archivo PDF: 156.71 Kb.

RESUMEN

La preeclampsia es un síndrome hipertensivo que se presenta a partir de la semana 20 de gestación. El objetivo de este trabajo es describir la producción y los mecanismos de acción de las lipoxinas inducidas por la aspirina y proponerlas como una alternativa adecuada para modular los procesos oxidativos característicos de la preeclampsia y los ciclos proinflamatorios que inician con la cascada de activación del factor nuclearkappa B, y en consecuencia de sus productos. La preeclampsia se caracteriza por la producción de sustancias proinflamatorias, que inducen la activación de células endoteliales, directa o indirectamente, a través de la activación previa de los monocitos, los cuales pueden generar especies reactivas de oxígeno y expresar moléculas de adhesión que median la interacción con el endotelio, contribuyendo a su estado de disfunción, activación e inducción de la cascada de señalización del factor nuclear-kappa B. La aspirina por su parte, induce la producción de lipoxinas que inhiben la activación del factor nuclear-kappa B mediante el bloqueo de la proteína quinasa IkB, necesaria para desencadenar la activación de la vía canónica y no canónica de este factor nuclear.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Meis PJ, Goldenberg RL, Mercer BM. The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol. 1998;178:562-7.

2. Arngrimsson R, Bjornsson S, Geirsson RT, Bjornsson H, Walker JJ, Snaedal G. Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol. 1990;97:762-9.

3. Simpson LL. Maternal medical disease: risk of antepartum fetal death. Semin Perinatol. 2002;26:42-50.

4. Heyborne KD. Preeclampsia prevention: lessons from the low-dose aspirin therapy trials. Am J Obstet Gynecol. 2000;183:523-8.

5. Ogasawara MS, Iinuma Y, Aoki K, Katano K, Ozaki Y, Suzumori K. Low-dose aspirin is effective for treatment of recurrent miscarriage in patients with decreased coagulation factor XII. Fertil Steril. 2001;76:203-4.

6. Roberge S, Giguere Y, Villa P. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012;29:551-6.

7. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007:CD004659.

8. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-13.

9. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirinlike drugs. Nat New Biol. 1971;231:232-5.

10. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci US A. 1995;92:9475-9.

11. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008;3:279-312.

12. Gil-Villa AM, Norling LV, Serhan CN, Cordero D, Rojas M, Cadavid A. Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. Prostaglandins Leukot Essent Fatty Acids. 2012;87:127-34.

13. Ariel A, Chiang N, Arita M, Petasis NA, Serhan CN. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol. 2003;170:6266-72.

14. Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A. 2002;99:13266- 71.

15. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46:1077-85.

16. Redman CW, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta. 2000;21:597-602.

17. Hou L, Zhu Y, Ma X, Li J, Zhang W. Serum protein microarray analysis of patients with preeclampsia. Mol Med Report. 2012;6:83-7.

18. Faas MM, van Pampus MG, Anninga ZA. Plasma from preeclamptic women activates endothelial cells via monocyte activation in vitro. J Reprod Immunol. 2010;87:28-38.

19. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180:499-506.

20. Mikic AN, Brkic S, Maric D, Sekulic B, Cetkovic A, Mitic G. Thiobarbituric acid reactive substances as marker of oxidative stress in pregnancies with pre-eclampsia. Med Pregl. 2011;64:377-80.

21. Serdar Z, Gur E, Colakoethullary M, Develioethlu O, Sarandol E. Lipid and protein oxidation and antioxidant function in women with mild and severe preeclampsia. Arch Gynecol Obstet. 2003;268:19-25.

22. Peracoli MT, Bannwart CF, Cristofalo R. Increased reactive oxygen species and tumor necrosis factor-alpha production by monocytes are associated with elevated levels of uric acid in pre-eclamptic women. Am J Reprod Immunol. 2011;66:460-7.

23. Flood-Nichols SK, Stallings JD, Gotkin JL, Tinnemore D, Napolitano PG, Ippolito DL. Elevated ratio of maternal plasma ApoCIII to ApoCII in preeclampsia. Reprod Sci. 2011;18:493-502.

24. Gervasi MT, Chaiworapongsa T, Naccasha N. Phenotypic and metabolic characteristics of maternal monocytes and granulocytes in preterm labor with intact membranes. Am J Obstet Gynecol. 2001;185:1124-9.

25. Luppi P, Tse H, Lain KY, Markovic N, Piganelli JD, DeLoia JA. Preeclampsia activates circulating immune cells with engagement of the NF-kappaB pathway. Am J Reprod Immunol. 2006;56:135-44.

26. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011;21:103-15.

27. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell. 1998;95:749-58.

28. Gringhuis SI, den Dunnen J, Litjens M. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat Immunol. 2009;10:203-13.

29. Verma UN, Yamamoto Y, Prajapati S, Gaynor RB. Nuclear role of I kappa B Kinasegamma/ NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa Bdependent gene expression. J Biol Chem. 2004;279:3509-15.

30. Urso C, Caimi G. Oxidative stress and endothelial dysfunction. Minerva Med. 2011;102:59-77.

31. Hayman R, Brockelsby J, Kenny L, Baker P. Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J Soc Gynecol Investig. 1999;6:3-10.

32. Lockwood CJ, Huang SJ, Krikun G. Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. Semin Thromb Hemost. 2011;37:158-64.

33. Astudillo AM, Balgoma D, Balboa MA, Balsinde J. Dynamics of arachidonic acid mobilization by inflammatory cells. Biochimica et biophysica acta. 2012;1821:249-56.

34. Fleming I. Cytochrome P450-dependent eicosanoid production and crosstalk. Curr Opin Lipidol. 2011;22:403-9.

35. Haeggstrom JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev. 2011;111:5866-98.

36. Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev. 2011;111:5821-65.

37. Masferrer JL, Zweifel BS, Manning PT. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:3228-32.

38. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol. 2002;447:1-9.

39. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255-8.

40. Saunders MA, Sansores-Garcia L, Gilroy DW, Wu KK. Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem. 2001;276:18897- 904.

41. Yoshida Y, Singh I, Darby CP. Effect of salicylic acid and calcium on mitochondrial functions. Acta Neurol Scand. 1992;85:191-6.

42. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci U S A. 1997;94:2869-73.

43. Yan F, Polk DB. Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells. J Biol Chem. 1999;274:36631-6.

44. Yoo CG, Lee S, Lee CT, Kim YW, Han SK, Shim YS. Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2001;280:L3-9.

45. Cieslik K, Zhu Y, Wu KK. Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway. J Biol Chem. 2002;277:49304-10.

46. DeWitt DL, el-Harith EA, Kraemer SA. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem. 1990;265:5192-8.

47. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem. 1994;269:13207-15.

48. Wang YP, Wu Y, Li LY. Aspirin-triggered lipoxin A4 attenuates LPS-induced proinflammatory responses by inhibiting activation of NF-kappaB and MAPKs in BV-2 microglial cells. J Neuroinflammation. 2011;8:95.

49. Grosser N, Abate A, Oberle S. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003;308:956-60.

50. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirintriggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids. 2005;73:163-77.